Uremic toxins: Do we know enough to explain uremia?

Blood Purification

Volumn 26, Issue 1, 2008, Pages 77-81

  Vanholder, R ^a   Meert, N ^a   Schepers, E ^a   Glorieux, G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chronic kidney disease; Chronic kidney disease, pathophysiology; Uremia; Uremic toxins

Indexed keywords

UREMIC TOXIN;

CLINICAL STUDY; CONFERENCE PAPER; DIALYSIS; HUMAN; IN VITRO STUDY; MEDICAL LITERATURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; SCREENING; UREMIA;

HEART; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; UREMIA;

EID: 38049081114     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110570     Document Type: Conference Paper

References (31)

1. Vanholder R, De Smet R: Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815-1823.
2. Vanholder R, Argiles A, Baurmeister U, et al: Uremic toxicity: present state of the art. Int J Artif Organs 2001;24:695-725.
3. Vanholder R, Massy Z, Argiles A, et al: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005;20:1048-1056.
4. Van Biesen W, De Bacquer D, Verbeke F, et al: The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007;28:478-483.
5. Vanholder R, De Smet R, Glorieux G, et al: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
6. Weissinger EM, Kaiser T, Meert N, et al: Proteomics: a novel tool to unravel the pathophysiology of uraemia. Nephrol Dial Transplant 2004;19:3068-3077.
7. Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity. Pediatr Nephrol 2007; in press.
8. Vanholder R, Van Laecke S, Glorieux G: The middle molecule hypothesis thirty years after: lost and rediscovered in the universe of uremic toxicity? J Nephrol 2007; in press.
9. Ogilvie A, Blasius R, Schulze-Lohoff E, Sterzel RB: Adenine dinucleotides: a novel class of signalling molecules. J Auton Pharmacol 1996;16:325-328.
10. Heidenreich S, Tepel M, Schluter H, Harrach B, Zidek W: Regulation of rat mesangial cell growth by diadenosine phosphates. J Clin Invest 1995;95:2862-2867.
11. Jankowski J, Hagemann J, Yoon MS, et al: Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int 2001;59:1134-1141.
12. Jankowski V, Tolle M, Vanholder R, et al: Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med 2005;11:223-227.
13. Martinez AW, Recht NS, Hostetter TH, Meyer TW: Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005;16:3430-3436.
14. De Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K: Gas chromatographicmass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005;51:1535-1538.
15. Schepers E, Meert N, Glorieux G, et al: p-Cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007;22:592-596.
16. De Smet R, Van Kaer J, Van Vlem B, et al: Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003;49:470-478.
17. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y: Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006;69:1081-1087.
18. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003;64:2238-2243.
19. Eloot S, Torremans A, De Smet R, et al: Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int 2005;67:1566-1575.
20. Cohen G, Glorieux G, Thornalley P, et al: Review on uraemic toxins III - recommendations for handling uraemic retention solutes in vitro: towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007, Aug 27 (Epub ahead of print).
21. Vanholder R, Meert N, Schepers E, et al: Review on uraemic solutes. II. Variability in reported concentrations: causes and consequences. Nephrol Dial Transplant 2007;22:3115-3121.
22. Fliser D, Novak J, Thongboonkerd V, et al: Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007;18:1057-1071.
23. Meert N, Schepers E, De Smet R, et al: Inconsistency of reported uremic toxin concentrations. Artif Organs 2007;31:600-611.
24. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
25. Valli A, Suliman ME, Meert N, et al: Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta 2007;379:87-94.
26. Selmeci L, Szekely M, Soos P, et al: Human blood plasma advanced oxidation protein product correlates with fibrinogen levels. Free Radic Res 2006;40:952-958.
27. Eknoyan G, Beck GJ, Cheung AK, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
28. Cheung AK, Levin NW, Greene T, et al: Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003;14:3251-3263.
29. Delmez JA, Yan G, Bailey J, et al: Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO study. Am J Kidney Dis 2006;47:131-138.
30. 2-microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006;17:546-555.
31. Locatelli F, Hannedouche T, Jacobson S, et al: The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. J Nephrol 1999;12:85-88.